Cite
Dolutegravir/Abacavir/Lamivudine versus Current ART in Virally Suppressed Patients (STRIIVING): A 48-Week, Randomized, Non-Inferiority, Open-Label, Phase IIIb Study
MLA
Trottier, Benoît, et al. “Dolutegravir/Abacavir/Lamivudine versus Current ART in Virally Suppressed Patients (STRIIVING): A 48-Week, Randomized, Non-Inferiority, Open-Label, Phase IIIb Study.” Antiviral Therapy, vol. 22, no. 4, May 2017, pp. 295–305. EBSCOhost, https://doi.org/10.3851/IMP3166.
APA
Trottier, B., Lake, J. E., Logue, K., Brinson, C., Santiago, L., Brennan, C., Koteff, J. A., Wynne, B., Hopking, J., Granier, C., & Aboud, M. (2017). Dolutegravir/Abacavir/Lamivudine versus Current ART in Virally Suppressed Patients (STRIIVING): A 48-Week, Randomized, Non-Inferiority, Open-Label, Phase IIIb Study. Antiviral Therapy, 22(4), 295–305. https://doi.org/10.3851/IMP3166
Chicago
Trottier, Benoît, Jordan E Lake, Ken Logue, Cynthia Brinson, Lizette Santiago, Clare Brennan, Justin A Koteff, et al. 2017. “Dolutegravir/Abacavir/Lamivudine versus Current ART in Virally Suppressed Patients (STRIIVING): A 48-Week, Randomized, Non-Inferiority, Open-Label, Phase IIIb Study.” Antiviral Therapy 22 (4): 295–305. doi:10.3851/IMP3166.